Search
for
Sort by
Research 361–390 of 1000+
- Spironolactone May be a Cause of Hormonally Associated Vestibulodynia and Female Sexual Arousal Disorder
- 105 Spironolactone May be a Cause of Hormonally Associated Vestibulodynia and Female Genital Arousal Disorder
- Hypersensitivity Diseases
- PRIDE syndrome associated with panitumumab treatment – case report and literature review
- RASopathic Skin Eruptions during Vemurafenib Therapy
- Metformin in dermatology: an overview
- Antiandrogens and Androgen Inhibitors
- Skin Diseases Associated With COVID-19: A Narrative Review
- Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib
- Cetuximab-induced hypertrichosis of the scalp and eyelashes
- A Case of Hair Change and Acneiform Eruption Induced by ZD1839 (Iressa$^{(R)}$)
- Shared Spaces: Decoding Dual Dermatoses in a Single Dermatome
- Topical Allium cepa Ethanol Extract Restores SOD and VEGF Without Increasing Hair Length in UV-B-Exposed Wistar Rats
- Dermatological Drugs, Topical Agents, and Cosmetics
- Dermatologic Signs and Symptoms of Substance Abuse
- Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study
- Alopecia Areata: Hair and Nail Findings in a Patient Undergoing Talquetamab Therapy for Multiple Myeloma
- Sorafenib stimulates human skin type mast cell degranulation and maturation
- Anatomical and Dermatologic Manifestations of Estrogen Deficiency in Postmenopausal Women: A Systematic Review
- TOC
- Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
- Wound Healing and the Use of Medicinal Plants
- Management of hypotrichosis of the eyelashes: Focus on bimatoprost
- The management of EGFR inhibitor adverse events: a case series and treatment paradigm
- Essential Thrombocythemia: The Dermatologic Point of View
- Dermabrasion
- Beta-caryophyllene enhances wound healing through multiple routes
- “PRIDE” Complex
- Sorafenib-induced Facial Acneiform Eruption
- 576 INTASYL PH-762: Intratumoral immunotherapy targeting PD-1